Review



du145  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC du145
    OR51E1 agonists reduce LNCaP cell viability, but expression alone does not predict patient outcome. (A) LNCaP cells were treated with increasing concentrations (0.1–1 mM) of NA or BA for 48 h, and cell viability was measured using the Cell Counting Kit-8 assay. Values were normalized to untreated controls. (B) The effect of NA on cell viability was assessed in control and OR51E1 knockout LNCaP cells after 48 h of NA (0.5 mM) treatment. (C) Relative OR51E1 mRNA expression in LNCaP, <t>DU145,</t> and PC3 prostate cancer cell lines was assessed by reverse transcription-quantitative PCR. Expression levels were normalized to β-actin. Representative PCR products were visualized by agarose gel electrophoresis. (D) LNCaP, DU145 and PC3 cells were cultured with various concentrations of NA for 48 h, and cell viability was measured. Data represent the mean ± SEM of three independent experiments. Statistical significance was determined using an unpaired Student's t-test. (E) OR51E1 expression across pathological stages of prostate cancer. OR51E1 mRNA expression levels were compared between normal prostate tissues from the GTEx dataset and prostate adenocarcinoma samples from TCGA stratified by pathological stage: Stage I (T2b), Stage II (T2b and T2c), Stage III (T3a and 3b), and Stage IV (T4). Transcript expression values (RSEM TPM) were obtained from the UCSC Xena Browser using the TCGA-TARGET-GTEx TOIL RNA-seq recompute dataset. Statistical significance was determined using an unpaired Student's t-test. (F and G) Kaplan-Meier survival curves for (F) overall survival and (G) progression-free interval stratified by OR51E1 expression levels. Red and blue lines indicate high- and low-expression groups, respectively. Survival probabilities were compared using the log-rank test, and P-values are shown in each panel. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. OR51E1, olfactory receptor 51E1; BA, butyric acid; NA, nonanoic acid; GTEx, Genotype-Tissue Expression; TCGA, The Cancer Genome Atlas; ns, not significant.
    Du145, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 8544 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/du145/product/ATCC
    Average 99 stars, based on 8544 article reviews
    du145 - by Bioz Stars, 2026-05
    99/100 stars

    Images

    1) Product Images from "Sphingosine-1-phosphate receptor 1 enhances olfactory receptor 51E1-mediated inhibition of proliferation via Src/JNK signaling in prostate cancer cells"

    Article Title: Sphingosine-1-phosphate receptor 1 enhances olfactory receptor 51E1-mediated inhibition of proliferation via Src/JNK signaling in prostate cancer cells

    Journal: Oncology Reports

    doi: 10.3892/or.2026.9103

    OR51E1 agonists reduce LNCaP cell viability, but expression alone does not predict patient outcome. (A) LNCaP cells were treated with increasing concentrations (0.1–1 mM) of NA or BA for 48 h, and cell viability was measured using the Cell Counting Kit-8 assay. Values were normalized to untreated controls. (B) The effect of NA on cell viability was assessed in control and OR51E1 knockout LNCaP cells after 48 h of NA (0.5 mM) treatment. (C) Relative OR51E1 mRNA expression in LNCaP, DU145, and PC3 prostate cancer cell lines was assessed by reverse transcription-quantitative PCR. Expression levels were normalized to β-actin. Representative PCR products were visualized by agarose gel electrophoresis. (D) LNCaP, DU145 and PC3 cells were cultured with various concentrations of NA for 48 h, and cell viability was measured. Data represent the mean ± SEM of three independent experiments. Statistical significance was determined using an unpaired Student's t-test. (E) OR51E1 expression across pathological stages of prostate cancer. OR51E1 mRNA expression levels were compared between normal prostate tissues from the GTEx dataset and prostate adenocarcinoma samples from TCGA stratified by pathological stage: Stage I (T2b), Stage II (T2b and T2c), Stage III (T3a and 3b), and Stage IV (T4). Transcript expression values (RSEM TPM) were obtained from the UCSC Xena Browser using the TCGA-TARGET-GTEx TOIL RNA-seq recompute dataset. Statistical significance was determined using an unpaired Student's t-test. (F and G) Kaplan-Meier survival curves for (F) overall survival and (G) progression-free interval stratified by OR51E1 expression levels. Red and blue lines indicate high- and low-expression groups, respectively. Survival probabilities were compared using the log-rank test, and P-values are shown in each panel. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. OR51E1, olfactory receptor 51E1; BA, butyric acid; NA, nonanoic acid; GTEx, Genotype-Tissue Expression; TCGA, The Cancer Genome Atlas; ns, not significant.
    Figure Legend Snippet: OR51E1 agonists reduce LNCaP cell viability, but expression alone does not predict patient outcome. (A) LNCaP cells were treated with increasing concentrations (0.1–1 mM) of NA or BA for 48 h, and cell viability was measured using the Cell Counting Kit-8 assay. Values were normalized to untreated controls. (B) The effect of NA on cell viability was assessed in control and OR51E1 knockout LNCaP cells after 48 h of NA (0.5 mM) treatment. (C) Relative OR51E1 mRNA expression in LNCaP, DU145, and PC3 prostate cancer cell lines was assessed by reverse transcription-quantitative PCR. Expression levels were normalized to β-actin. Representative PCR products were visualized by agarose gel electrophoresis. (D) LNCaP, DU145 and PC3 cells were cultured with various concentrations of NA for 48 h, and cell viability was measured. Data represent the mean ± SEM of three independent experiments. Statistical significance was determined using an unpaired Student's t-test. (E) OR51E1 expression across pathological stages of prostate cancer. OR51E1 mRNA expression levels were compared between normal prostate tissues from the GTEx dataset and prostate adenocarcinoma samples from TCGA stratified by pathological stage: Stage I (T2b), Stage II (T2b and T2c), Stage III (T3a and 3b), and Stage IV (T4). Transcript expression values (RSEM TPM) were obtained from the UCSC Xena Browser using the TCGA-TARGET-GTEx TOIL RNA-seq recompute dataset. Statistical significance was determined using an unpaired Student's t-test. (F and G) Kaplan-Meier survival curves for (F) overall survival and (G) progression-free interval stratified by OR51E1 expression levels. Red and blue lines indicate high- and low-expression groups, respectively. Survival probabilities were compared using the log-rank test, and P-values are shown in each panel. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. OR51E1, olfactory receptor 51E1; BA, butyric acid; NA, nonanoic acid; GTEx, Genotype-Tissue Expression; TCGA, The Cancer Genome Atlas; ns, not significant.

    Techniques Used: Expressing, Cell Counting, Control, Knock-Out, Reverse Transcription, Real-time Polymerase Chain Reaction, Agarose Gel Electrophoresis, Cell Culture, RNA Sequencing, Olfactory



    Similar Products

    du145  (ATCC)
    99
    ATCC du145
    OR51E1 agonists reduce LNCaP cell viability, but expression alone does not predict patient outcome. (A) LNCaP cells were treated with increasing concentrations (0.1–1 mM) of NA or BA for 48 h, and cell viability was measured using the Cell Counting Kit-8 assay. Values were normalized to untreated controls. (B) The effect of NA on cell viability was assessed in control and OR51E1 knockout LNCaP cells after 48 h of NA (0.5 mM) treatment. (C) Relative OR51E1 mRNA expression in LNCaP, <t>DU145,</t> and PC3 prostate cancer cell lines was assessed by reverse transcription-quantitative PCR. Expression levels were normalized to β-actin. Representative PCR products were visualized by agarose gel electrophoresis. (D) LNCaP, DU145 and PC3 cells were cultured with various concentrations of NA for 48 h, and cell viability was measured. Data represent the mean ± SEM of three independent experiments. Statistical significance was determined using an unpaired Student's t-test. (E) OR51E1 expression across pathological stages of prostate cancer. OR51E1 mRNA expression levels were compared between normal prostate tissues from the GTEx dataset and prostate adenocarcinoma samples from TCGA stratified by pathological stage: Stage I (T2b), Stage II (T2b and T2c), Stage III (T3a and 3b), and Stage IV (T4). Transcript expression values (RSEM TPM) were obtained from the UCSC Xena Browser using the TCGA-TARGET-GTEx TOIL RNA-seq recompute dataset. Statistical significance was determined using an unpaired Student's t-test. (F and G) Kaplan-Meier survival curves for (F) overall survival and (G) progression-free interval stratified by OR51E1 expression levels. Red and blue lines indicate high- and low-expression groups, respectively. Survival probabilities were compared using the log-rank test, and P-values are shown in each panel. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. OR51E1, olfactory receptor 51E1; BA, butyric acid; NA, nonanoic acid; GTEx, Genotype-Tissue Expression; TCGA, The Cancer Genome Atlas; ns, not significant.
    Du145, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/du145/product/ATCC
    Average 99 stars, based on 1 article reviews
    du145 - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    99
    ATCC human du145 metastatic pca cell line
    The PDPK1/AKT/FLT DPI and tenovin-6 (T6) show high anti-cancer efficacy in murine tumoroids and human PCa cell lines (A) Dose-response curves for DPI (top) and T6 (bottom) for in vivo and in vitro Pten KO (left), Pten/Stat3 KO (middle), and Pten/Tp53 KO (right) tumoroids. Points represent means of technical duplicates per tumoroid line ( N = 3). Curve fitting was performed using GraphPad Prism 8.0.2. (B) Bar graphs showing means and ±SD of half-maximal inhibitory concentration (IC50) for DPI (top) and T6 (bottom) for in vivo and in vitro tumoroid lines of all genotypes ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA, Tukey’s test). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05. (C) Bar graphs depicting means and ±SD of IC50 values of DPI (left) and T6 (right) on human PCa cell lines. 22RV1: primary PCa; LNCaP: metastatic PCa; <t>DU145,</t> PC3: metastatic castration-resistant PCa ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05; ∗∗ p ≤ 0.01. (D) Heatmaps of synergy scores calculated with the highest single agent (HSA) model for DPI and enzalutamide (left), and T6 and enzalutamide (right) on the human LNCaP cell line. Values > 0 represent synergistic effects, and values < 0 represent antagonistic effects. IC50 concentrations of respective compounds are underlined ( N = 3). See also .
    Human Du145 Metastatic Pca Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human du145 metastatic pca cell line/product/ATCC
    Average 99 stars, based on 1 article reviews
    human du145 metastatic pca cell line - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    99
    ATCC du145 pc cell line
    The PDPK1/AKT/FLT DPI and tenovin-6 (T6) show high anti-cancer efficacy in murine tumoroids and human PCa cell lines (A) Dose-response curves for DPI (top) and T6 (bottom) for in vivo and in vitro Pten KO (left), Pten/Stat3 KO (middle), and Pten/Tp53 KO (right) tumoroids. Points represent means of technical duplicates per tumoroid line ( N = 3). Curve fitting was performed using GraphPad Prism 8.0.2. (B) Bar graphs showing means and ±SD of half-maximal inhibitory concentration (IC50) for DPI (top) and T6 (bottom) for in vivo and in vitro tumoroid lines of all genotypes ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA, Tukey’s test). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05. (C) Bar graphs depicting means and ±SD of IC50 values of DPI (left) and T6 (right) on human PCa cell lines. 22RV1: primary PCa; LNCaP: metastatic PCa; <t>DU145,</t> PC3: metastatic castration-resistant PCa ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05; ∗∗ p ≤ 0.01. (D) Heatmaps of synergy scores calculated with the highest single agent (HSA) model for DPI and enzalutamide (left), and T6 and enzalutamide (right) on the human LNCaP cell line. Values > 0 represent synergistic effects, and values < 0 represent antagonistic effects. IC50 concentrations of respective compounds are underlined ( N = 3). See also .
    Du145 Pc Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/du145 pc cell line/product/ATCC
    Average 99 stars, based on 1 article reviews
    du145 pc cell line - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    Image Search Results


    OR51E1 agonists reduce LNCaP cell viability, but expression alone does not predict patient outcome. (A) LNCaP cells were treated with increasing concentrations (0.1–1 mM) of NA or BA for 48 h, and cell viability was measured using the Cell Counting Kit-8 assay. Values were normalized to untreated controls. (B) The effect of NA on cell viability was assessed in control and OR51E1 knockout LNCaP cells after 48 h of NA (0.5 mM) treatment. (C) Relative OR51E1 mRNA expression in LNCaP, DU145, and PC3 prostate cancer cell lines was assessed by reverse transcription-quantitative PCR. Expression levels were normalized to β-actin. Representative PCR products were visualized by agarose gel electrophoresis. (D) LNCaP, DU145 and PC3 cells were cultured with various concentrations of NA for 48 h, and cell viability was measured. Data represent the mean ± SEM of three independent experiments. Statistical significance was determined using an unpaired Student's t-test. (E) OR51E1 expression across pathological stages of prostate cancer. OR51E1 mRNA expression levels were compared between normal prostate tissues from the GTEx dataset and prostate adenocarcinoma samples from TCGA stratified by pathological stage: Stage I (T2b), Stage II (T2b and T2c), Stage III (T3a and 3b), and Stage IV (T4). Transcript expression values (RSEM TPM) were obtained from the UCSC Xena Browser using the TCGA-TARGET-GTEx TOIL RNA-seq recompute dataset. Statistical significance was determined using an unpaired Student's t-test. (F and G) Kaplan-Meier survival curves for (F) overall survival and (G) progression-free interval stratified by OR51E1 expression levels. Red and blue lines indicate high- and low-expression groups, respectively. Survival probabilities were compared using the log-rank test, and P-values are shown in each panel. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. OR51E1, olfactory receptor 51E1; BA, butyric acid; NA, nonanoic acid; GTEx, Genotype-Tissue Expression; TCGA, The Cancer Genome Atlas; ns, not significant.

    Journal: Oncology Reports

    Article Title: Sphingosine-1-phosphate receptor 1 enhances olfactory receptor 51E1-mediated inhibition of proliferation via Src/JNK signaling in prostate cancer cells

    doi: 10.3892/or.2026.9103

    Figure Lengend Snippet: OR51E1 agonists reduce LNCaP cell viability, but expression alone does not predict patient outcome. (A) LNCaP cells were treated with increasing concentrations (0.1–1 mM) of NA or BA for 48 h, and cell viability was measured using the Cell Counting Kit-8 assay. Values were normalized to untreated controls. (B) The effect of NA on cell viability was assessed in control and OR51E1 knockout LNCaP cells after 48 h of NA (0.5 mM) treatment. (C) Relative OR51E1 mRNA expression in LNCaP, DU145, and PC3 prostate cancer cell lines was assessed by reverse transcription-quantitative PCR. Expression levels were normalized to β-actin. Representative PCR products were visualized by agarose gel electrophoresis. (D) LNCaP, DU145 and PC3 cells were cultured with various concentrations of NA for 48 h, and cell viability was measured. Data represent the mean ± SEM of three independent experiments. Statistical significance was determined using an unpaired Student's t-test. (E) OR51E1 expression across pathological stages of prostate cancer. OR51E1 mRNA expression levels were compared between normal prostate tissues from the GTEx dataset and prostate adenocarcinoma samples from TCGA stratified by pathological stage: Stage I (T2b), Stage II (T2b and T2c), Stage III (T3a and 3b), and Stage IV (T4). Transcript expression values (RSEM TPM) were obtained from the UCSC Xena Browser using the TCGA-TARGET-GTEx TOIL RNA-seq recompute dataset. Statistical significance was determined using an unpaired Student's t-test. (F and G) Kaplan-Meier survival curves for (F) overall survival and (G) progression-free interval stratified by OR51E1 expression levels. Red and blue lines indicate high- and low-expression groups, respectively. Survival probabilities were compared using the log-rank test, and P-values are shown in each panel. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. OR51E1, olfactory receptor 51E1; BA, butyric acid; NA, nonanoic acid; GTEx, Genotype-Tissue Expression; TCGA, The Cancer Genome Atlas; ns, not significant.

    Article Snippet: LNCaP cells were obtained from the Korean Cell Line Bank, and Du145 and PC3 cells were purchased from the American Type Culture Collection.

    Techniques: Expressing, Cell Counting, Control, Knock-Out, Reverse Transcription, Real-time Polymerase Chain Reaction, Agarose Gel Electrophoresis, Cell Culture, RNA Sequencing, Olfactory

    The PDPK1/AKT/FLT DPI and tenovin-6 (T6) show high anti-cancer efficacy in murine tumoroids and human PCa cell lines (A) Dose-response curves for DPI (top) and T6 (bottom) for in vivo and in vitro Pten KO (left), Pten/Stat3 KO (middle), and Pten/Tp53 KO (right) tumoroids. Points represent means of technical duplicates per tumoroid line ( N = 3). Curve fitting was performed using GraphPad Prism 8.0.2. (B) Bar graphs showing means and ±SD of half-maximal inhibitory concentration (IC50) for DPI (top) and T6 (bottom) for in vivo and in vitro tumoroid lines of all genotypes ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA, Tukey’s test). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05. (C) Bar graphs depicting means and ±SD of IC50 values of DPI (left) and T6 (right) on human PCa cell lines. 22RV1: primary PCa; LNCaP: metastatic PCa; DU145, PC3: metastatic castration-resistant PCa ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05; ∗∗ p ≤ 0.01. (D) Heatmaps of synergy scores calculated with the highest single agent (HSA) model for DPI and enzalutamide (left), and T6 and enzalutamide (right) on the human LNCaP cell line. Values > 0 represent synergistic effects, and values < 0 represent antagonistic effects. IC50 concentrations of respective compounds are underlined ( N = 3). See also .

    Journal: Cell Reports Methods

    Article Title: Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss

    doi: 10.1016/j.crmeth.2026.101370

    Figure Lengend Snippet: The PDPK1/AKT/FLT DPI and tenovin-6 (T6) show high anti-cancer efficacy in murine tumoroids and human PCa cell lines (A) Dose-response curves for DPI (top) and T6 (bottom) for in vivo and in vitro Pten KO (left), Pten/Stat3 KO (middle), and Pten/Tp53 KO (right) tumoroids. Points represent means of technical duplicates per tumoroid line ( N = 3). Curve fitting was performed using GraphPad Prism 8.0.2. (B) Bar graphs showing means and ±SD of half-maximal inhibitory concentration (IC50) for DPI (top) and T6 (bottom) for in vivo and in vitro tumoroid lines of all genotypes ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA, Tukey’s test). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05. (C) Bar graphs depicting means and ±SD of IC50 values of DPI (left) and T6 (right) on human PCa cell lines. 22RV1: primary PCa; LNCaP: metastatic PCa; DU145, PC3: metastatic castration-resistant PCa ( N = 3). Statistical analysis was performed using GraphPad Prism 8.0.2 (one-way ANOVA). p > 0.05 if not specified otherwise, ∗ p ≤ 0.05; ∗∗ p ≤ 0.01. (D) Heatmaps of synergy scores calculated with the highest single agent (HSA) model for DPI and enzalutamide (left), and T6 and enzalutamide (right) on the human LNCaP cell line. Values > 0 represent synergistic effects, and values < 0 represent antagonistic effects. IC50 concentrations of respective compounds are underlined ( N = 3). See also .

    Article Snippet: Human DU145 metastatic PCa cell line , ATCC , HTB-81, RRID:CVCL_0105.

    Techniques: In Vivo, In Vitro, Concentration Assay